标题 |
Safety, efficacy, & pharmacodynamic (PD) activity of 12 weeks treatment with oral RIG-I agonist, inarigivir (IRIG), plus 48 weeks of tenofovir alafenamide in adult patients with chronic hepatitis B: a phase 2 collaboration study
口服RIG-I激动剂伊那吉韦(IRIG)联合替诺福韦阿拉酚胺48周治疗成人慢性乙型肝炎患者的安全性、有效性和药效学(PD)活性:一项2期合作研究
|
网址 | |
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 | The International Liver Congress: European Association for the Study of the Liver (EASL) Virtual; 2021 23-26 June.;Lim YS, Hui AJ, Jang JW, Tak WY, Ahn SH, Jang BK, et al |
求助人 | |
下载 |